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A B S T R A C T
Familial hemophagocytic lymphohistiocytosis (FLH) is an autosomal recessively inherited multisystem disease. This
defect in cellular cytotoxicity is a life threatening condition characterized by fever, rash, splenomegaly, cytopenias and
neurologic manifestations. PRF1, UNC13D and STX11 gene defects underlie in about 40–50% of primary cases. Chemo-
immunotherapy followed by hematopoietic stem cell transplantation improved disease outcome. We report a case of a
6-week-old boy who presented with a fever, diffuse rash, disseminated intravascular coagulation, hypofibrinogenemia,
hypertrigliceridemia, hepatosplenomegaly, leukocytosis with 90% of lymphocytes, granulocytopenia, anemia, trombo-
cytopenia, hyperferritinemia and pathological findings in cerebrospinal fluid. The patient had decreased frequency of
NK cells and low NK cell activity in peripheral blood. Bone marrow aspiration analysis showed degenerative changes of
histocyte cells, with preserved cytophages (lymphophages and erythrophages) consistent with hematophagocytic syndro-
me. Given that the molecular diagnosis of the known mutations in genes PRF1 and UNC13D showed a mutation in
UNC13D, the diagnosis of familial hemophagocytic lymphohistiocytosis subtype 3 was established. HLH-2004 chemo-
therapy protocol was performed and partial remission with residual central nervous system disease was achieved. He-
matopoietic stem cell transplantation was successfully performed with an unrelated HLA-matched donor. Familiar HLH
is generaly a progressive and fatal disease. Early diagnosis with molecular genetic analysis and chemoimmunotherapy
followed by hematopoietic stem-cell transplantation is the best approach.
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Introduction
Hemophagocytic lymphohistiocytosis (HLH) is a rare
condition, but without exceptions fatal if not treated. It
presents itself as overactive macrophages and T-lympho-
cytes. HLH can be both an inherited and acquired con-
diton and is thus divided into two main groups: familial
(primary) hemophagocytic lymphohistiocytosis (FLH) and
secondary hemophagocytic lymphohistiocytosis (SHLH).
SHLH is most commonly linked to an Epstein-Barr
virus infection, although infections with other viruses or
fungi have been reported. SHLH may also be associated
with malignant, genetic or autoimmune diseases1,2. Im-
mune diffeciency syndromes such as Chediak-Higashi
syndrome 1, Griscelly syndrome 2 and X-linked proli-
ferative syndrome have also been related to HLH3.
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However, familial form of HLH is an autosomal reces-
sive disorder seen mostly in infancy and childhood and is
invariably fatal if untreated. Incidence of FHL has been
estimated at 1.2 cases per million, corresponding to 1:50 000
births4. Inherited genetic defects result in a cellular im-
munologic disorder that leads to hyperactivation, prolif-
eration and infiltration of macrophages and T-lypho-
cytes. The presence of at least five of the eight common
clinical findings (prolongued fever, cytopenias, hepato-
splenomegaly, hypertriglyceridemia, hypofibrinogene-
mia, hemophagocytosis, low or absent natural killer
(NK) cell activity, hyperferritinemia and high plasma
concentrations of soluble CD25) can be sufficient to es-
tablish a diagnosis. The diagnosis can also be confirmed
by detecting disease-causing mutations in disease-associ-
ated genes (PRF1, UNC13D, STX11)5.
The treatment of this condition involves chemother-
apy and immunotherapy in order to achieve clinical sta-
bility prior to allogeneic hematopoietic stem cell trans-
plant (HSCT) as the only curative therapy. Here we
present a case of a 6-week-old infant with an FHL sub-
type 3.
Case Report
A six-week-old male infant was admitted to our hospi-
tal due to diarrhea with slight traces of blood in the stool
and confluent maculo-petechial rash after receiving anti-
biotic treatment for a respiratory infection. He had a
normal prenatal history. Family history has no particu-
larities apart from two great grandmother’s children de-
ceased shortly after birth from an unknown cause. The
patient is the first child of unrelated parents and was
born from mother’s first and only pregnancy which was
without any significant events until a week before birth
when the complications were manifested in terms of hy-
pertension. Birth was at term, with vacuum extraction.
Infancy period was without any abnormalities and with
regular development.
Upon initial physical examination he was found to be
without fever but with hepatomegaly 6 cm below the rib
cage and splenomegaly 8 cm below the rib cage. Labora-
tory findings revealed high leukocyte levels at 25.28
109/L (granulocytes 1%, lymphocytes 90%, monocyte 4%,
reactive lymphocytes 5%), erythrocytes 3.351012/L, he-
moglobin 100 g/L, hematocrit 0.286, low thrombocyte
levels at 28109/L, alanine aminotransferase 80 U/L,
aspartate aminotransferase 63 U/L, gamma glutamyl
transpeptidase 404 U/L, lactat dehydrogenase 549 U/L,
blood glucose 6.6 mmol/L, ferritin >5000 ng/mL, choles-
terol 2.68 mmol/L, triglycerides 4.76 mmol/L, high-den-
sity lipoprotein 0.35 mmol/L, low-density lipoprotein
0.17 mmol/L, prothrombin time was not detectable, fi-
brinogen was also undetectable, thrombin time 34.7 sec-
onds, antithrombin III (ATIII) 76.2%, D-dimer 6.3 mg/L.
The following day the boy’s coagulation test results
worsened, all of which were indicative of the develop-
ment of disseminated intravascular coagulation. He de-
veloped a fever and his general condition also deterio-
rated so he was treated with intravenous broad spectrum
antibiotic along with fresh frozen plasma, thrombocytes,
cryoprecipitate and ATIII substitutions. First bone mar-
row aspirate was taken on the 5th day of the admission
and showed no abnormalities. Due to thrombocytopenia
we tested for antithrombocytic antibodies in peripheral
blood and found binded antithrombocyte antibodies of
IgG class. At that time the boy received intravenous im-
munoglobulin therapy but with no clinical impact. Leu-
kopenia and anemia slowly developed along with throm-
bocytopenia. Rapid exacerbation together with constant-
ly deteriorating laboratory results (leukocytes 1.7109/L,
thrombocytes 27109/L and hemoglobin 80 g/L) on the
9th day of the admission indicated another bone marrow
aspiration. Bone marrow aspiration analysis showed me-
diocellular bone marrow with regeneratory granulo-
poiesis mainly up to a stage of metamyelocyte and a few
mature forms. Plenty of megakaryocytes were found to-
gether with abundant erythropoiesis. We observed dege-
nerative changes of histocyte cells, alone and in clusters,
with preserved cytophages (lymphophages and erythro-
phages) consistent with hemophagocytic syndrome (Figu-
re 1). Decreased frequency of NK cells and low NK cell
activity (<1%) were detected in peripheral blood. Intra-
cellular perforin expression in peripheral blood mono-
nuclear cells determined by flow cytometry was within
the age-dependent reference range. Cytotoxic lympho-
cyte activity was performed. The cytotoxicity was imme-
diately above the limit set as pathological (<10 LU). NK
cell degranulation was deficient.
EBV PCR results as well as EBVCA IgM serology
were negative. PCR and correspondingly RT-PCR analy-
sis results for herpes simplex virus, cytomegalovirus and
parvovirus B19 were negative. Serologic testing detected
no IgM antibodies for parvovirus B19 or adenovirus. All
other infectious, neoplastic or hereditary metabolic dis-
eases have also been ruled out. Genetic testing revealed a
single UNC13D mutation which was together with all
the other results compliant to the diagnosis of familial
hemophagocytic lymphohistiocytosis subtype 3.
We commenced treatment according to the hemo-
phagocytic lymphohistiocytosis protocol HLH-2004. It
includes etoposide, dexamethasone, cyclosporine A up-
front and, in selected patients, intrathecal therapy with
methotrexate and corticosteroids. Subsequent hema-
topoietic stem cell transplantation (HSCT) is recom-
G. Jakovljevi} et al.: Familial Hemophagocytic Lymphohistiocytosis in an Infant, Coll. Antropol. 34 (2010) 2: 631–634
632
Fig. 1. The bone marrow aspirate smears: a) phagocytosis;
b) lympho- and granulophagocytosis in the same macrophage.
mended for patients with familial disease or molecular
diagnosis and patients with severe and persistent or re-
activated disease4. Already after one week from the be-
ginning of the treatment we observed clinical improve-
ment, organomegaly regression and complete blood cells
count (CBC) improvement. The boy reacted well to the
induction therapy, but had diarrhea with positivity to
Clostridium difficile toxins and perianal ulceration posi-
tive to Pseudomonas aeruginosa. Therefore, we conduct-
ed a targeted antibiotic treatment, with all supportive
therapy recommended by the protocol. He received irra-
diated and filtered erythrocytes and thrombocytes a few
times. After central nervous system (CNS) involvement
had been detected [number of cells in CSF 928/3 with
79% lymphocytes (71% CD3 positive), 20% macrophages
and 1% plasma cells] (Figure 2), the boy received intra-
thecal therapy four times. Head MRI showed no lesions.
Upon finalization of the induction the boy’s general con-
dition improved. Liver and spleen size were within nor-
mal parameters, CBC was normal and coagulation tests
were satisfying. Since CSF analysis showed persistent
signs of CNS involvement (residual cells in CSF 150/3),
we introduced intravenous corticosteroids (dexametha-
sone 10 mg/m2/day for 7 days and then reduced to 5
mg/m2/day) and kept those doses for another two weeks.
We observed a partial regression in the number of cells in
CSF, so dexamethasone pulses were continued with eto-
poside every second week during the continuation ther-
apy. The entire time the patient was on oral cyclosporin
A. He had no HLA-identical related donor and a search
for a matching unrelated donor was begun.
After six months of chemotherapy the boy was re-
ferred to another hospital for unrelated umbilical cord
blood hematopoietic stem cell transplantation. Reduced
intensity conditioning regimen included fludarabine,
treosulfan and anti-thymocyte immunoglobulin. In the
post transplantation period the patient presented a se-
vere graft-versus-host disease including skin, gut and
liver. Immunosuppressive treatment consisting of cyclo-
sporine and prednisolon started at the time of HSCT was
continued through more than six-month period after the
procedure, during which it was slowly tapered off. Six
months following the HSCT the patient was in good con-
dition and with no signs of graft-versus-host disease. Do-
nor and recipient chimerism test showed almost full do-
nor population of transplanted cells. His immunity will
take another year or two to function adequately. 18
months following the diagnosis the patient is in remis-
sion and shows no signs of illness.
Discussion
HLH is a rare autosomal recessive disease, presented
as a severe hyperinflammatory syndrome with intense
activation of macrophages and T lymphocytes. The dis-
ease usually develops in the first few months of life or
rarely in utero, but it is invariably fatal if not treated6. So
far four genes have been related to the development of
HLH, further dividing the disease into four subtypes.
FHL subtype 1 was found in four inbred Pakistani fami-
lies in which locus was identified on chromosome 9q21.3–
q22 but the gene is still unknown. FHL subtype 2 is con-
nected to more than 50 mutations of the PRF1 gene cod-
ing for perforin-1 protein, well known as a cytolytic
effector. FHL subtype 3 is defined by mutations of the
UNC13D gene coding for unc-13 homolog D protein in-
volved in cytolytic secretory pathway. FHL subtype 4 is
linked to 3 recurrent mutations of STX11 gene coding for
syntaxin-11 known for its role in vesical transport7. De-
pending on the origin, 13–50% of patients with FHLH
have mutations in the perforin gene, and 17–30% in
UNC13D gene, while STX11 mutations have been found
only in patients of Kurdish/Turkish origin3.
FHL is a rare disease but with a well defined diagnos-
tic guidelines. The diagnostic criteria based on the rec-
ommendations of the Histiocyte Society include at least
five of the eight following findings: fever, splenomegaly,
cytopenias affecting at least two of three cell lineages in
peripheral blood, hypertriglyceridemia and/or hypofibri-
nogemia, hemophagocytosis in bone marrow, spleen or
lymph nodes, low or absent natural killer (NK) cell func-
tion activity, hyperferritinemia and high levels of soluble
CD25 (soluble IL-2 receptor). Biallelic mutations in PRF1,
UNC13D (also known as MUNC13-4) or STX11 genes
also confirm the diagnosis of FHL.
The treatment of this disease according to the hemo-
phagocytic lymphohistiocytosis protocols HLH-94 and
HLH-2004 includes chemotherapy and immunotherapy
followed by HSCT. Survival improved significantly with
introduction of HSCT in the treatment protocol and led
to three-year survival at approximately 64%8.
In our case, the patient presented with fever, pan-
cytopenia, hepatosplenomegaly, hypertriglyceridemia,
hypofibrinogenemia, hyperferritinemia, low NK-cell ac-
tivity and hemophagocytosis observed in the bone mar-
row, thus meeting seven out of eight clinical criteria for
the diagnosis of FHL. Additional genetic testing further
confirmed the right diagnosis. Our patient was tested
negative for PRF1 mutation, but only one mutation of
UNC13D was found. Although FHL is an autosomal re-
cessive disease, that kind of finding has been reported
and it might be explained by the presence of second pre-
sumed mutation in a different HLH-causing gene or
within the introns of the UNC13D gene or its promoter
region9. The distribution of the mutations in Croatian
FHLH patients is unknown, as this is the first patient in
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Fig. 2. The cerebrospinal fluid: a) erythrophagocytosis;
b) lymphocytes (1), a macrophage (2) and a monocyte (3).
which the genetic testing was performed to our knowl-
edge. Further aggravating circumstance was the involve-
ment of central nervous system which has been corre-
lated with a worse outcome10. But with slight alteration
of the treatment protocol in form of continuing intrave-
nous dexamethasone therapy (10 mg/m2 / per day), we
managed to achieve partial remission, sufficient to sub-
due the patient to an HSCT.
We believe our case states that early diagnosis and
rapid and adequate therapy is of great essence in treating
FHL. Considering the patient’s bad condition and cen-
tral nervous system involvement as negative predictors,
we might conclude that physicians’ heightened sense of
awareness, timely diagnosis and early beginning of the
treatment were important to prevent indubitably fatal
outcome and provide a good recovery.
Acknowledgements
We would like to thank Judith Johnson from Cin-
cinnati Children’s Hospital Medical Center for PRF1 and
MUNC 13–4 mutation analyses, Yenan Bryceson from
Karolinska University for performing immunological
testing. We would particularly like to thank Professor
Jan-Inge Henter and Professor Jacek Winiarski from
Karolinska University Hospital for their expert advice in
conducting diagnostics and therapy as well as heading
the transplantation procedure.
R E F E R E N C E S
1. IMASHUKU S, Int J Hematol, 66 (1997) 135. — 2. HENTER JI,
SAMUELSSON-HORNE A, ARICÒ M, EGELER RM, ELINDER G,
FILIPOVICH AH, GADNER H, IMASHUKU S, KOMP D, LADISH S,
WEBB D, JANKA G, Blood, 100 (2002) 2367. — 3. HORNE A, RAMME
KG, RUDD E, ZHENG C, WALI Y, AL-LAMKI Z, GÜRGEY A, YALMAN
N, NORDENSKJÖLD M, HENTER JI, Br J Haematol, 143 (2008) 75. —
4. HENTER JI, ELINDER G, OST A, Semin Oncol, 18 (1996) 340. — 5.
HENTER JI, HORNE A, ARICÒ M, EGELER RM, FILIPOVICH AH,
IMASHUKU S, LADISH S, McCLAIN K, WEBB D, WINIARSKI J, JAN-
KA G, Pediatr Blood Cancer, 48 (2007) 124. — 6. ROGANOVI] J, KVE-
NI] B, JONJI] N, SEILI-BEKAFIGO I, KARDUM-SKELIN I, Coll An-
tropol, 34 (2010) 285. — 7. ZHANG K, FILIPOVICH AH, JOHNSON J,
Hemophagocytic lymphohistiocytosis, Familial, GeneReview, accessed 16.
08. 2008. Available from: URL: http://www.ncbi.nlm.nih.gov/bookshelf/
br.fcgi?book=gene&part=hlh. — 8. HORNE A, JANKA G, MAARTEN
EGELER R, GADNER H, IMASHUKU S, LADISCH S, LOCATELLI S,
LOCATELLI F, MONTGOMERY SM, WEBB D, WINIARSKI J, FILI-
POVISH AH, HENTER JI, Br J Hematol, 129 (2005) 622. — 9. ZUR
STADT U, BEUTEL K, KOLBERG S, SCHNEPPENHEIM R, KABISCH
H, JANKA G, HENNIES HC, Hum Mutat, 27 (2006) 62. — 10. HORNE
A, TROTTESTAM H, ARICÒ M, EGELER RM, FILIPOVICH AH, GAD-
NER H, IMASHUKU S, LADISCH S, WEBB D, JANKA G, HENTER JI,
Br J Hematol, 140 (2008) 327.
G. Jakovljevi}
Department of Hematology and Oncology, Zagreb Children’s Hospital, Klai}eva 16, Zagreb, Croatia
e-mail: gordanajakovljevic@yahoo.com
FAMILIJARNA HEMOFAGOCITNA LIMFOHISTIOCITOZA U DJE^AKA STAROG [EST TJEDANA
S A @ E T A K
Familijarna hemofagocitna limfohistiocitoza (FLH) je autosomalno recesivna nasljedna multisistemska bolest. Ovaj
poreme}aj stani~ne citotoksi~nosti je `ivotno ugro`avaju}e stanje karakterizirano vru}icom, osipom, splenomegalijom,
citopenijom i neurolo{kim manifestacijama. PRF1, UNC13D i STX11 genski defekti nalaze se u podlozi 40–50% slu~a-
jeva FLH. Kemoimunoterapija i naknadna transplantacija hematopoetskih mati~nih stanica zna~ajno pobolj{avaju ishod
bolesti. Ovdje smo prikazali slu~aj dje~aka starog {est tjedana s vru}icom, difuznim osipom, diseminiranom intravas-
kularnom koagulacijom, hipofibrinogenemijom, hipertrigiceridemijom, hepatosplenomegalijom, leukocitozom s vi{e od
90% limfocita, granulocitopenijom, anemijom, trombocitopenijom, hiperferitinemijom i patolo{kim nalazom u cerebro-
spinalnom likvoru. U perifernoj krvi na|en je smanjen postotak i niska aktivnost NK stanica. U analiziranom aspiratu
ko{tane sr`i otkrivene su degenerativno promijenjene histiocitne stanice i o~uvani citofazi (limfofazi i eritrofazi), {to je
odgovaralo hemofagocitnom sindromu. Uz molekularnu potvrdu mutacije UNC13D gena, postavljena je dijagnoza FHL
podtipa 3. Primijenjen je HLH-2004 kemoterapijski protokol i postignuta parcijalna remisija uz prisutnu rezidualnu
bolest sredi{njeg `iv~anog sustava. Transplantacija hematopoetskih mati~nih stanica od nesrodnog HLA-podobnog da-
rivatelja uspje{no je izvedena. FHL je progresivna i fatalna bolest ~iji se bolji ishod posti`e ranim postavljanjem dijag-
noze i provo|enjem pravovremene kemoimunoterapije s alogenom transplantacijom hematopoetskih mati~nih stanica.
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